More than matrix: The multifaceted role of decorin in cancer

European Journal of Cell Biology

Volumn 92, Issue 1, 2013, Pages 1-11

  Sofeu Feugaing, David Denis ^a   Götte, Martin ^b   Viola, Manuela ^b,c  

^a UNIVERSITY OF BUEA   (Cameroon)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Cancer; Decorin; Extracellular matrix; Matrikine; Therapeutic potential

Indexed keywords

CELL SURFACE RECEPTOR; CHEMOKINE RECEPTOR CXCR4; CHONDROITIN; DECORIN; DERMATAN SULFATE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GLYCOSAMINOGLYCAN;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CELL MIGRATION; CELL PROLIFERATION; ENDOCYTOSIS; EXTRACELLULAR MATRIX; GENE TARGETING; HUMAN; LUNG METASTASIS; METASTASIS; METASTASIS INHIBITION; NEOPLASM; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR DOWN REGULATION; SHORT SURVEY; SIGNAL TRANSDUCTION; STROMA CELL; TRANSGENICS; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; WOUND HEALING;

ANIMALS; DECORIN; EXTRACELLULAR MATRIX; HUMANS; NEOPLASMS; PROTEIN BINDING;

EID: 84870362178     PISSN: 01719335     EISSN: 16181298     Source Type: Journal    
DOI: 10.1016/j.ejcb.2012.08.004     Document Type: Short Survey

References (144)

1. Asimakopoulou A.P., Theocharis A.D., Tzanakakis G.N., Karamanos N.K. The biological role of chondroitin sulfate in cancer and chondroitin-based anticancer agents. In Vivo 2008, 22:385-389.
2. Bhide V.M., Laschinger C.A., Arora P.D., Lee W., Hakkinen L., Larjava H., Sodek J., McCulloch C.A. Collagen phagocytosis by fibroblasts is regulated by decorin. J. Biol. Chem. 2005, 280:23103-23113.
3. Bi X., Tong C., Dockendorff A., Bancroft L., Gallagher L., Guzman G., Iozzo R.V., Augenlicht L.H., Yang W. Genetic deficiency of decorin causes intestinal tumour formation through disruption of intestinal cell maturation. Carcinogenesis 2008, 29:1435-1440.
4. Bi X., Pohl N.M., Qian Z., Yang G.R., Gou Y., Guzman G., Kajdacsy-Balla A., Iozzo R.V., Yang W. Decorin-mediated inhibition of colorectal cancer growth and migration is associated with E-cadherin in vitro and in mice. Carcinogenesis 2012, 332:326-330.
5. Biaoxue R., Xiguang C., Hua L., Hui M., Shuanying Y., Wei Z., Wenli S., Jie D. Decreased expression of decorin and p57(KIP2) correlates with poor survival and lymphatic metastasis in lung cancer patients. Int. J. Biol. Markers 2011, 26:9-21.
6. Bidanset D.J., Guidry C., Rosenberg L.C., Choi H.U., Timpl R., Hook M. Binding of the proteoglycan decorin to collagen type VI. J. Biol. Chem. 1992, 267:5250-5256.
7. Biglari A., Bataille D., Naumann U., Weller M., Zirger J., Castro M.G., Lowenstein P.R. Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. Cancer Gene Ther. 2004, 11:721-732.
8. Border W.A., Noble N.A., Yamamoto T., Harper J.R., Yamaguchi Y., Pierschbacher M.D., Ruoslahti E. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 1992, 360:361-364.
9. Brandan E., Retamal C., Cabello-Verrugio C., Marzolo M.P. The low density lipoprotein receptor-related protein functions as an endocytic receptor for decorin. J. Biol. Chem. 2006, 281:31562-31571.
10. Brown L.F., Guidi A.J., Schnitt S.J., Van De Water L., Iruela-Arispe M.L., Yeo T.K., Tognazzi K., Dvorak H.F. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin. Cancer Res. 1999, 5:1041-1056.
11. Buraschi S., Pal N., Tyler-Rubinstein N., Owens R.T., Neill T., Iozzo R.V. Decorin antagonizes Met receptor activity and down-regulates {beta}-catenin and Myc levels. J. Biol. Chem. 2010, 285:42075-42085.
12. Burgess A.W. EGFR family: structure physiology signalling and therapeutic targets. Growth Factors 2008, 26:263-274.
13. Campioni M., Ambrogi V., Pompeo E., Citro G., Castelli M., Spugnini E.P., Gatti A., Cardelli P., Lorenzon L., Baldi A., Mineo T.C. Identification of genes down-regulated during lung cancer progression: a cDNA array study. J. Exp. Clin. Cancer Res. 2008, 27:38.
14. Campo S., Campo G.M., Avenoso A., D'Ascola A., Musolino C., Calabro L., Bellomo G., Quartarone E., Calatroni A. Lymphocytes from patients with early stage of B-cell chronic lymphocytic leukaemia and long survival synthesize decorin. Biochimie 2006, 88:1933-1939.
15. Carlson E.C., Liu C.-Y., Chikama T., Hayashi Y., Kao C.W.-C., Birk D.E., Funderburgh J.L., Jester J.V., Kao W.W.-Y. Keratocan, a cornea-specific keratan sulfate proteoglycan, is regulated by lumican. J. Biol. Chem. 2005, 280(27):25541-25547.
16. Chopra R.K., Pearson C.H., Pringle G.A., Fackre D.S., Scott P.G. Dermatan sulphate is located on serine-4 of bovine skin proteodermatan sulphate. Demonstration that most molecules possess only one glycosaminoglycan chain and comparison of amino acid sequences around glycosylation sites in different proteoglycans. Biochem. J. 1985, 232:277-279.
17. Cooney C.A., Jousheghany F., Yao-Borengasser A., Phanavanh B., Gomes T., Kieber-Emmons A.M., Siegel E.R., Suva L.J., Ferrone S., Kieber-Emmons T., Monzavi-Karbassi B. Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells. Breast Cancer Res. 2011, 13:R58.
18. Csordás G., Santra M., Reed C.C., Eichstetter I., McQuillan D.J., Gross D., Nugent M.A., Hajnoczky G., Iozzo R.V. Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumour growth in vivo. J. Biol. Chem. 2000, 275:32879-32887.
19. Danielson K.G., Baribault H., Holmes D.F., Graham H., Kadler K.E., Iozzo R.V. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J. Cell Biol. 1997, 136:729-743.
20. Day A.A., McQuillan C.I., Termine J.D., Young M.R. Molecular cloning and sequence analysis of the cDNA for small proteoglycan II of bovine bone. Biochem. J. 1987, 248:801-805.
21. Douglas T., Heinemann S., Bierbaum S., Scharnweber D., Worch H. Fibrillogenesis of collagen types I, II, and III with small leucine-rich proteoglycans decorin and biglycan. Biomacromolecules 2006, 7(8):2388-2393.
22. Fransson L.A., Belting M., Jönsson M., Mani K., Moses J., Oldberg A. Biosynthesis of decorin and glypican. Matrix Biol. 2000, 19:367-376.
23. Fuster M.M., Esko J.D. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat. Rev. Cancer 2005, 5:526-542.
24. Goldoni S., Owens R.T., McQuillan D.J., Shriver Z., Sasisekharan R., Birk D.E., Campbell S., Iozzo R.V. Biologically active decorin is a monomer in solution. J. Biol. Chem. 2004, 279:6606-6612.
25. Goldoni S., Seidler D.G., Heath J., Fassan M., Baffa R., Thakur M.L., Owens R.T., McQuillan D.J., Iozzo R.V. An antimetastatic role for decorin in breast cancer. Am. J. Pathol. 2008, 173:844-855.
26. Goldoni S., Humphries A., Nyström A., Sattar S., Owens R.T., McQuillan D.J., Ireton K., Iozzo R.V. Decorin is a novel antagonistic ligand of the Met receptor. J. Cell Biol. 2009, 185:743-754.
27. Götte M., Greve B., Kelsch R., Müller-Uthoff H., Weiss K., Kharabi Masouleh B., Sibrowski W., Kiesel L., Buchweitz O. The adult stem cell marker musashi-1 modulates endometrial carcinoma cell cycle progression and apoptosis via notch-1 and p21(WAF1/CIP1). Int. J. Cancer 2011, 129:2042-2049.
28. Götte M., Kresse H. Defective glycosaminoglycan substitution of decorin in a patient with progeroid syndrome is a direct consequence of two point mutations in the galactosyltransferase I (beta4GalT-7) gene. Biochem. Genet. 2005, 43:65-77.
29. Götte M., Kresse H., Hausser H. Endocytosis of decorin by bovine aortic endothelial cells. off. Eur. J. Cell Biol. 1995, 66:226-233.
30. Götte M., Sofeu Feugaing D.D., Kresse H. Biglycan is internalized via a chlorpromazine-sensitive route. Cell. Mol. Biol. Lett. 2004, 9:475-481.
31. Grant D.S., Yenisey C., Rose R.W., Tootell M., Santra M., Iozzo R.V. Decorin suppresses tumour cell-mediated angiogenesis. Oncogene 2002, 21:4765-4777.
32. Guidetti G.F., Bartolini B., Bernardi B., Tira M.E., Berndt M.C., Balduini C., Torti M. Binding of von Willebrand factor to the small proteoglycan decorin. FEBS Lett. 2004, 574(1-3):95-100.
33. Harada T., Shinohara M., Nakamura S., Oka M. An immunohistochemical study of the extracellular matrix in oral squamous cell carcinoma and its association with invasive and metastatic potential. Virchows Arch. 1994, 424:257-266.
34. Hausser H., Kresse H. Binding of heparin and of the small proteoglycan decorin to the same endocytosis receptor proteins leads to different metabolic consequences. J. Cell Biol. 1991, 114:45-52.
35. Hausser H., Schönherr E., Muller M., Liszio C., Bin Z., Fisher L.W., Kresse H. Receptor-mediated endocytosis of decorin: involvement of leucine-rich repeat structures. Arch. Biochem. Biophys. 1998, 349:363-370.
36. Hausser H., Wedekind P., Sperber T., Peters R., Hasilik A., Kresse H. Isolation and cellular localization of the decorin endocytosis receptor. Eur. J. Cell Biol. 1996, 71:325-331.
37. Hedbom E., Heinegård D. Binding of fibromodulin and decorin to separate sites on fibrillar collagens. J. Biol. Chem. 1993, 268(36):27307-27312.
38. Hildebrand A., Romaris M., Rasmussen L.M., Heinegard D., Twardzik D.R., Border W.A., Ruoslahti E. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem. J. 1994, 302(Pt 2):527-534.
39. Hocking A.M., Shinomura T., McQuillan D.J. Leucine-rich repeat glycoproteins of the extracellular matrix. Matrix Biol. 1998, 17:1-19.
40. Hoppe W., Rauch U., Kresse H. Degradation of endocytosed dermatan sulfate proteoglycan in human fibroblasts. J. Biol. Chem. 1988, 263:5926-5932.
41. Hu Y., Sun H., Owens R.T., Wu J., Chen Y.Q., Berquin I.M., Perry D., O'Flaherty J.T., Edwards I.J. Decorin suppresses prostate tumour growth through inhibition of epidermal growth factor and androgen receptor pathways. Neoplasia 2009, 11:1042-1053.
42. Hulit J., Lee R.J., Li Z., Wang C., Katiyar S., Yang J., Quong A.A., Wu K., Albanese C., Russell R., Di Vizio D., Koff A., Thummala S., Zhang H., Harrell J., Sun H., Muller W.J., Inghirami G., Lisanti M.P., Pestell R.G. p27Kip1 repression of ErbB2-induced mammary tumour growth in transgenic mice involves Skp2 and Wnt/beta-catenin signaling. Cancer Res. 2006, 66:8529-8541.
43. Iozzo R.V. The family of the small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth. Crit. Rev. Biochem. Mol. Biol. 1997, 32:141-174.
44. Iozzo R.V. The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins. J. Biol. Chem. 1999, 274:18843-18846.
45. Iozzo R.V., Buraschi S., Genua M., Xu S.Q., Solomides C.C., Peiper S.C., Gomella L.G., Owens R.C., Morrione A. Decorin antagonizes IGF receptor I (IGF-IR) function by interfering with IGF-IR activity and attenuating downstream signaling. J. Biol. Chem. 2011, 286:34712-34721.
46. Iozzo R.V., Moscatello D.K., McQuillan D.J., Eichstetter I. Decorin is a biological ligand for the epidermal growth factor receptor. J. Biol. Chem. 1999, 274:4489-4492.
47. Jarvelainen H., Puolakkainen P., Pakkanen S., Brown E.L., Hook M., Iozzo R.V., Sage E.H., Wight T.N. A role for decorin in cutaneous wound healing and angiogenesis. Wound Repair Regen. 2006, 14:443-452.
48. Kao W.W.-Y., Funderburgh J.L., Xia Y., Liu C.-Y., Conrad G.W. Focus on molecules: lumican. Exp. Eye Res. 2006, 82(1):3-4.
49. Karousou E.G., Viola M., Vigetti D., Genasetti A., Rizzi M., Clerici M., Bartolini B., Luca G.D., Passi A. Analysis of glycosaminoglycans by electrophoretic approach. Curr. Pharm. Anal. 2008, 4:78-89.
50. Khan G.A., Girish G.V., Lala N., Di Guglielmo G.M., Lala P.K. Decorin is a novel VEGFR-2-binding antagonist for the human extravillous trophoblast. Mol. Endocrinol. 2011, 25(8):1431-1443.
51. Keene D.R., San Antonio J.D., Mayne R., McQuillan D.J., Sarris G., Santoro S.A., Iozzo R.V. Decorin binds near the C terminus of type I collagen. J. Biol. Chem. 2000, 275:21801-21804.
52. Kelemen L.E., Couch F.J., Ahmed S., Dunning A.M., Pharoah P.D.P., Easton D.F., Fredericksen Z.S., Vierkant R.A., Pankratz V.S., Goode E.L., Scott C.G., Rider D.N., Wang X., Cerhan J.R., Vachon C.M. Genetic variation in stromal proteins decorin and lumican with breast cancer: investigations in two case-control studies. Breast Cancer Res. 2008, 10:R98.
53. Kinsella M.G., Bressler S.L., Wight T.N. The regulated synthesis of versican, decorin, and biglycan: extracellular matrix proteoglycans that influence cellular phenotype. Crit. Rev. Eukaryot. Gene Expr. 2004, 14:203-234.
54. Kobe B., Deisenhofer J. Crystal structure of porcine ribonuclease inhibitor, a protein with leucine-rich repeats. Nature 1993, 366:751-756.
55. Koninger J., Giese N.A., di Mola F.F., Berberat P., Giese T., Esposito I., Bachem M.G., Buchler M.W., Friess H. Overexpressed decorin in pancreatic cancer: potential tumour growth inhibition and attenuation of chemotherapeutic action. Clin. Cancer Res. 2004, 10:4776-4783.
56. Koninger J., Giese T., di Mola F.F., Wente M.N., Esposito I., Bachem M.G., Giese N.A., Buchler M.W., Friess H. Pancreatic tumour cells influence the composition of the extracellular matrix. Biochem. Biophys. Res. Commun. 2004, 322:943-949.
57. Kresse H., Hausser H., Schönherr E. Small proteoglycans. Experientia 1993, 49:403-416.
58. Kresse H., Liszio C., Schonherr E., Fisher L.W. Critical role of glutamate in a central leucine-rich repeat of decorin for interaction with type I collagen. J. Biol. Chem. 1997, 272:18404-18410.
59. Kresse H., Schönherr E. Proteoglycans of the extracellular matrix and growth control. J. Cell. Physiol. 2001, 189:266-274.
60. Kreuger J., Spillmann D., Li J.P., Lindahl U. Interactions between heparan sulfate and proteins: the concept of specificity. J. Cell Biol. 2006, 174(3):323-327.
61. Krusius T., Ruoslahti E. Primary structure of an extracellular matrix proteoglycan core protein deduced from cloned cDNA. Proc. Natl. Acad. Sci. U.S.A. 1986, 83:7683-7687.
62. Lane H.A., Beuvink I., Motoyama A.B., Daly J.M., Neve R.M., Hynes N.E. ErbB2 potentiates breast tumour proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol. Cell. Biol. 2000, 20:3210-3223.
63. Laremore T.N., Ly M., Zhang Z., Solakyildirim K., McCallum S.A., Owens R.T., Linhardt R.J. Domain structure elucidation of human decorin glycosaminoglycans. Biochem. J. 2010, 431(2):199-205.
64. Lě M.G., Douc-Rasy S., Ahomadegbe J.C., Spielmann M., Guérin M., Riou G. Association of c-erbB2-gene amplification with poor prognosis in non-inflammatory breast carcinomas but not in carcinomas of the inflammatory type. Int. J. Cancer 1994, 58:763-768.
65. Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., Fong S.F., Csiszar K., Giaccia A., Weninger W., Yamauchi M., Gasser D.L., Weaver V.M. Matrix crosslinking forces tumour progression by enhancing integrin signaling. Cell 2009, 139:891-906.
66. Leygue E., Snell L., Dotzlaw H., Troup S., Hiller-Hitchcock T., Murphy L.C., Roughley P.J., Watson P.H. Lumican and decorin are differentially expressed in human breast carcinoma. J. Pathol. 2000, 192:313-320.
67. Liang Z., Yoon Y., Votaw J., Goodman M.M., Williams L., Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 2005, 65:967-971.
68. Lu P., Weaver V.M., Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 2012, 196:395-406.
69. Ma W., Cai S., Du J., Tan Y., Chen H., Guo Z., Hu H., Fang R. SDF-1/54-DCN: a novel recombinant chimera with dual inhibitory effects on proliferation and chemotaxis of tumour cells. Biol. Pharm. Bull. 2008, 31:1086-1091.
70. Mann D.M., Yamaguchi Y., Bourdon M.A., Ruoslahti E. Analysis of glycosaminoglycan substitution in decorin by site-directed mutagenesis. J. Biol. Chem. 1990, 265:5317-5323.
71. Maquart F.X., Pasco S., Ramont L., Hornebeck W., Monboisse J.C. An introduction to matrikines: extracellular matrix-derived peptides which regulate cell activity. Implication in tumour invasion. Crit. Rev. Oncol. Hematol. 2004, 49:199-202.
72. Maquart F.X., Simeon A., Pasco S., Monboisse J.C. Regulation of cell activity by the extracellular matrix: the concept of matrikines. J. Soc. Biol. 1999, 193:423-428.
73. Mefford D., Mefford J. Stromal genes add prognostic information to proliferation and histoclinical markers: a basis for the next generation of breast cancer gene signatures. PLoS One 2012, 7:e37646.
74. Miyasaka Y., Enomoto N., Nagayama K., Izumi N., Marumo F., Watanabe M., Sato C. Analysis of differentially expressed genes in human hepatocellular carcinoma using suppression subtractive hybridization. Br. J. Cancer 2001, 85:228-234.
75. Monzavi-Karbassi B., Stanley J.S., Hennings L., Jousheghany F., Artaud C., Shaaf S., Kieber-Emmons T. Chondroitin sulfate glycosaminoglycans as major P-selectin ligands on metastatic breast cancer cell lines. Int. J. Cancer 2007, 120:1179-1191.
76. Moscatello D.K., Santra M., Mann D.M., McQuillan D.J., Wong A.J., Iozzo R.V. Decorin suppresses tumuor cell growth by activating the epidermal growth factor receptor. J. Clin. Invest. 1998, 101:406-412.
77. Nareyeck G., Seidler D.G., Troyer D., Rauterberg J., Kresse H., Schönherr E. Differential interactions of decorin and decorin mutants with type I and type VI collagens. Eur. J. Biochem. 2004, 271:3389-3398.
78. Nash M.A., Deavers M.T., Freedman R.S. The expression of decorin in human ovarian tumours. Clin. Cancer Res. 2002, 8:1754-1760.
79. Nash M.A., Loercher A.E., Freedman R.S. In vitro growth inhibition of ovarian cancer cells by decorin: synergism of action between decorin and carboplatin. Cancer Res. 1999, 59:6192-6196.
80. Neame P.J., Kay C.J., McQuillan D.J., Beales M.P., Hassell J.R. Independent modulation of collagen fibrillogenesis by decorin and lumican. Cell. Mol. Life Sci. 2000, 57:859-863.
81. Neill T., Painter H., Buraschi S., Owens R.T., Lisanti M.P., Schaefer L., Iozzo R.V. Decorin antagonizes the angiogenic network: concurrent inhibition of Met, hypoxia inducible factor 1α, vascular endothelial growth factor A, and induction of thrombospondin-1 and TIMP3. J. Biol. Chem. 2012, 287:5492-5506.
82. Niers T.M., Klerk C.P., DiNisio M., Van Noorden C.J., Buller H.R., Reitsma P.H., Richel D.J. Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit. Rev. Oncol. Hematol. 2007, 61:195-207.
83. Olayioye M.A. Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res. 2001, 3:385-389.
84. Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R., Carey V.J., Richardson A.L., Weinberg R.A. Stromal fibroblasts present in invasive human breast carcinomas promote tumour growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348.
85. 2+ in A431 carcinoma cells. J. Biol. Chem. 1998, 273:3121-3124.
86. Pucci-Minafra I., Cancemi P., Di Cara G., Minafra L., Feo S., Forlino A., Tira M.E., Tenni R., Martini D., Ruggeri A., Minafra S. Decorin transfection induces proteomic and phenotypic modulation in breast cancer cells 8701-BC. Connect. Tissue Res. 2008, 49:30-41.
87. Pulkkinen L., Kainulainen K., Krusius T., Makinen P., Schollin J., Gustavsson K.H., Peltonen L. Deficient expression of the gene coding for decorin in a lethal form of Marfan syndrome. J. Biol. Chem. 1990, 265:17780-17785.
88. Purushothaman A., Fukuda J., Mizumoto S., ten Dam G.B., van Kuppevelt T.H., Kitagawa H., Mikami T., Sugahara K. Functions of chondroitin sulfate/dermatan sulfate chains in brain development. Critical roles of E and iE disaccharide units recognized by a single chain antibody GD3G7. J. Biol. Chem. 2007, 282:19442-19452.
89. Raspanti M., Viola M., Forlino A., Tenni R., Gruppi C., Tira M.E. Glycosaminoglycans show a specific periodic interaction with type I collagen fibrils. J. Struct. Biol. 2008, 164:134-139.
90. Reed C.C., Gauldie J., Iozzo R.V. Suppression of tumourigenicity by adenovirus-mediated gene transfer of decorin. Oncogene 2002, 21:3688-3695.
91. Reed C.C., Iozzo R.V. The role of decorin in collagen fibrillogenesis and skin homeostasis. Glycoconj. J. 2002, 19:249-255.
92. Reed C.C., Waterhouse A., Kirby S., Kay P., Owens R.T., McQuillan D.J., Iozzo R.V. Decorin prevents metastatic spreading of breast cancer. Oncogene 2005, 24:1104-1110.
93. Ricciardelli C., Mayne K., Sykes P.J., Raymond W.A., McCaul K., Marshall V.R., Tilley W.D., Skinner J.M., Horsfall D.J. Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer. Clin. Cancer Res. 1997, 3(6):983-992.
94. Ruoslahti E., Yamaguchi Y. Proteoglycans as modulators of growth factor activities. Cell 1991, 64:867-869.
95. Santiago-Garcia J., Kodama T., Pitas R.E. The class A scavenger receptor binds to proteoglycans and mediates adhesion of macrophages to the extracellular matrix. J. Biol. Chem. 2003, 278:6942-6946.
96. Santra M., Eichstetter I., Iozzo R.V. An anti-oncogenic role for decorin. Down-regulation of ErbB2 leads to growth suppression and cytodifferentiation of mammary carcinoma cells. J. Biol. Chem. 2000, 275:35153-35161.
97. Santra M., Reed C.C., Iozzo R.V. Decorin binds to a narrow region of the epidermal growth factor (EGF) receptor, partially overlapping but distinct from the EGF-binding epitope. J. Biol. Chem. 2002, 277:35671-35681.
98. Santra M., Skorski T., Calabretta B., Lattime E.C., Iozzo R.V. De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:7016-7020.
99. Schaefer L., Macakova K., Raslik I., Micegova M., Grone H.J., Schönherr E., Robenek H., Echtermeyer F.G., Grassel S., Bruckner P., Schaefer R.M., Iozzo R.V., Kresse H. Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction. Am. J. Pathol. 2002, 160:1181-1191.
100. Schönherr E., Hausser H., Beavan L., Kresse H. Decorin-type I collagen interaction. Presence of separate core protein-binding domains. J. Biol. Chem. 1995, 270:8877-8883.
101. Schönherr E., Broszat M., Brandan E., Bruckner P., Kresse H. Decorin core protein fragment Leu155-Val260 interacts with TGF-beta but does not compete for decorin binding to type I collagen. Arch. Biochem. Biophys. 1998, 355:241-248.
102. Schönherr E., Levkau B., Schaefer L., Kresse H., Walsh K. Decorin-mediated signal transduction in endothelial cells. Involvement of Akt/protein kinase B in up-regulation of p21(WAF1/CIP1) but not p27(KIP1). J. Biol. Chem. 2001, 276:40687-40692.
103. Schönherr E., Sunderkotter C., Iozzo R.V., Schaefer L. Decorin, a novel player in the insulin-like growth factor system. J. Biol. Chem. 2005, 280:15767-15772.
104. Scott J.E. Proteoglycan-fibrillar collagen interactions. Biochem. J. 1988, 252:313-323.
105. Scott P.G., Dodd C.M. Self-aggregation of bovine skin proteodermatan sulphate promoted by removal of the three N-linked oligosaccharides. Connect. Tissue Res. 1990, 24:225-235.
106. Scott P.G., Grossmann J.G., Dodd C.M., Sheehan J.K., Bishop P.N. Light and X-ray scattering show decorin to be a dimer in solution. J. Biol. Chem. 2003, 278:18353-18359.
107. Scott P.G., McEwan P.A., Dodd C.M., Bergmann E.M., Bishop P.N., Bella J. Crystal structure of the dimeric protein core of decorin, the archetypal small leucine-rich repeat proteoglycan. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:15633-15638.
108. Seidler D.G., Schaefer L., Robenek H., Iozzo R.V., Kresse H., Schönherr E. A physiologic three-dimensional cell culture system to investigate the role of decorin in matrix organisation and cell survival. Biochem. Biophys. Res. Commun. 2005, 332(4):1162-1170.
109. Seidler D.G., Faiyaz-Ul-Haque M., Hansen U., Yip G.W., Zaidi S.H., Teebi A.S., Kiesel L., Götte M. Defective glycosylation of decorin and biglycan, altered collagen structure, and abnormal phenotype of the skin fibroblasts of an Ehlers-Danlos syndrome patient carrying the novel Arg270Cys substitution in galactosyltransferase I (beta4GalT-7). J. Mol. Med. (Berl.) 2006, 84:583-594.
110. Seidler D.G., Goldoni S., Agnew C., Cardi C., Thakur M.L., Owens R.T., McQuillan D.J., Iozzo R.V. Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation. J. Biol. Chem. 2006, 281:26408-26418.
111. Seo N.S., Hocking A.M., Höök M., McQuillan D.J. Decorin core protein secretion is regulated by N-linked oligosaccharide and glycosaminoglycan additions. J. Biol. Chem. 2005, 280(52):42774-42784.
112. Shintani K., Matsumine A., Kusuzaki K., Morikawa J., Matsubara T., Wakabayashi T., Araki K., Satonaka H., Wakabayashi H., Iino T., Uchida A. Decorin suppresses lung metastases of murine osteosarcoma. Oncol. Rep. 2008, 19:1533-1539.
113. Skandalis S.S., Kletsas D., Kyriakopoulou D., Stavropoulos M., Theocharis D.A. The greatly increased amounts of accumulated versican and decorin with specific post-translational modifications may be closely associated with the malignant phenotype of pancreatic cancer. Biochim. Biophys. Acta 2006, 1760:1217-1225.
114. Skandalis S.S., Theocharis A.D., Theocharis D.A., Papadas T., Vynios D.H., Papageorgakopoulou N. Matrix proteoglycans are markedly affected in advanced laryngeal squamous cell carcinoma. Biochim. Biophys. Acta 2004, 1689:152-161.
115. Skandalis S.S., Labropoulou V.T., Ravazoula P., Likaki-Karatza E., Dobra K., Kalofonos H.P., Karamanos N.K., Theocharis A.D. Versican but not decorin accumulation is related to malignancy in mammographically detected high density and malignant-appearing microcalcifications in non-palpable breast carcinomas. BMC Cancer 2011, 11:314-326.
116. Smetsers T.F., van de Westerlo E.M., ten Dam G.B., Overes I.M., Schalkwijk J., van Muijen G.N., van Kuppevelt T.H. Human single-chain antibodies reactive with native chondroitin sulfate detect chondroitin sulfate alterations in melanoma and psoriasis. J. Invest. Dermatol. 2004, 122(3):707-716.
117. Smid-Koopman E., Blok L.J., Chadha-Ajwani S., Helmerhorst T.J., Brinkmann A.O., Huikeshoven F.J. Gene expression profiles of human endometrial cancer samples using a cDNA-expression array technique: assessment of an analysis method. Br. J. Cancer 2000, 83:246-251.
118. Sofeu Feugaing D.D., Götte M., De La Motte C., Drazba J., Kresse H. Involvement of different uptake routes in decorin endocytosis. Mol. Biol. Cell 2002, 13. 341A-341A.
119. Sofeu Feugaing D.D., Kresse H., Greb R.R., Götte M. A novel 110-kDa receptor protein is involved in endocytic uptake of decorin by human skin fibroblasts. Sci. World J. 2006, 6:35-52.
120. Sofeu Feugaing D.D., Kresse H., Stenmark H., Greb R.R., Götte M. Endocytosis of the small dermatan sulfate proteoglycans decorin and biglycan utilizes partially diverging pathways. Eur. J. Cell Biol. 2005, 84. 119-119.
121. Sofeu Feugaing D.D., Tammi R., Echtermeyer F.G., Stenmark H., Kresse H., Smollich M., Schönherr E., Kiesel L., Götte M. Endocytosis of the dermatan sulfate proteoglycan decorin utilizes multiple pathways and is modulated by epidermal growth factor receptor signaling. Biochimie 2007, 89:637-657.
122. Spiro R.C., Countaway J.L., Gaarde W.A., Garcia J.A., Leisten J., O'Neill J.J., Smiley W.R., Stecker K., Harper J.R. Analysis of collagen-binding properties of human recombinant decorin. Mol. Biol. Cell 1994, 55:303.
123. Stock C., Jungmann O., Seidler D.G. Decorin and chondroitin-6 sulfate inhibit B16V melanoma cell migration and invasion by cellular acidification. J. Cell. Physiol. 2011, 226(10):2641-2650.
124. Svensson L., Heinegard D., Oldberg A. Decorin-binding sites for collagen type I are mainly located in leucine-rich repeats 4-5. J. Biol. Chem. 1995, 270:20712-20716.
125. Swindle C.S., Tran K.T., Johnson T.D., Banerjee P., Mayes A.M., Griffith L., Wells A. Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor. J. Cell Biol. 2001, 154:459-468.
126. Tenni R., Viola M., Welser F., Sini P., Giudici C., Rossi A., Tira M.E. Interaction of decorin with CNBr peptides from collagens I and II. Evidence for multiple binding sites and essential lysyl residues in collagen. Eur. J. Biochem. 2002, 269:1428-1437.
127. Theocharis A.D., Vynios D.H., Papageorgakopoulou N., Skandalis S.S., Theocharis D.A. Altered content composition and structure of glycosaminoglycans and proteoglycans in gastric carcinoma. Int. J. Biochem. Cell Biol. 2003, 35:376-390.
128. Tralhao J.G., Schaefer L., Micegova M., Evaristo C., Schönherr E., Kayal S., Veiga-Fernandes H., Danel C., Iozzo R.V., Kresse H., Lemarchand P. In vivo selective and distant killing of cancer cells using adenovirus-mediated decorin gene transfer. FASEB J. 2003, 17:464-466.
129. Tran K.T., Griffith L., Wells A. Extracellular matrix signaling through growth factor receptors during wound healing. Wound Repair Regen. 2004, 12:262-268.
130. Tran K.T., Lamb P., Deng J.S. Matrikines and matricryptins: implications for cutaneous cancers and skin repair. J. Dermatol. Sci. 2005, 40:11-20.
131. Troup S., Njue C., Kliewer E.V., Parisien M., Roskelley C., Chakravarti S., Roughley P.J., Murphy L.C., Watson P.H. Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin. Cancer Res. 2003, 9:207-214.
132. Trowbridge J.M., Gallo R.L. Dermatan sulfate: new functions from an old glycosaminoglycan. Glycobiology 2002, 12:117R-125R.
133. Tsara M.E., Theocharis A.D., Theocharis D.A. Compositional and structural alterations of proteoglycans in human rectum carcinoma with special reference to versican and decorin. Anticancer Res. 2002, 22:2893-2898.
134. Tsutsui S., Ohno S., Murakami S., Hachitanda Y., Oda S. Prognostic value of c-erbB2 expression in breast cancer. J. Surg. Oncol. 2002, 79:216-223.
135. Ursini-Siegel J., Schade B., Cardiff R.D., Muller W.J. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat. Rev. Cancer 2007, 7:389-397.
136. Vigetti D., Andrini O., Clerici M., Negrini D., Passi A., Moriondo A. Chondroitin sulfates act as extracellular gating modifiers on voltage-dependent ion channels. Cell. Physiol. Biochem. 2008, 22(1-4):137-146.
137. Viola M., Karousou E.G., Vigetti D., Genasetti A., Pallotti F., Guidetti G.F., Tira E., De Luca G., Passi A. Decorin from different bovine tissues: study of glycosaminoglycan chain by PAGEFS. J. Pharm. Biomed. Anal. 2006, 41:36-42.
138. Vogel K.G., Paulsson M., Heinegard D. Specific inhibition of type I and type II collagen fibrillogenesis by the small proteoglycan of tendon. Biochem. J. 1984, 223:587-597.
139. Weber I.T., Harrison R.W., Iozzo R.V. Model structure of decorin and implications for collagen fibrillogenesis. J. Biol. Chem. 1996, 271:31767-31770.
140. Wegrowski Y., Marquart F.X. Involvement of stromal proteoglycans in tumour progression. Crit. Rev. Oncol. Hematol. 2004, 49:259-268.
141. Wels J., Kaplan R.N., Rafii S., Lyden D. Migratory neighbors and distant invaders: tumour-associated niche cells. Genes Dev. 2008, 22:559-574.
142. Yamaguchi Y., Mann D.M., Ruoslahti E. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 1990, 346:281-284.
143. Yip G.W., Smollich M., Götte M. Therapeutic value of glycosaminoglycans in cancer. Mol. Cancer Ther. 2006, 5:2139-2148.
144. Zhu J.X., Goldoni S., Bix G., Owens R.T., McQuillan D.J., Reed C.C., Iozzo R.V. Decorin evokes protracted internalization and degradation of the epidermal growth factor receptor via caveolar endocytosis. J. Biol. Chem. 2005, 280:32468-32479.